BrainsWay Deep TMS - Innovative, Noninvasive Treatment
BrainsWay Deep TMS represents the next generation of noninvasive treatment options for Depression, OCD, and Smoking Addiction. Learn about Brainsway Deep TMS treatment >>
Overview
BrainsWay is a company specializing in noninvasive neurostimulation treatments for mental health disorders, headquartered in Burlington, MA. The company develops and operates its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, which targets conditions such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is the first TMS company to receive FDA clearance for three indications, supported by pivotal studies demonstrating clinical efficacy. Founded in 2003, BrainsWay is conducting additional clinical trials of Deep TMS for various psychiatric, neurological, and addiction disorders. The company aims to increase global awareness and access to its Deep TMS treatment.
Details
- Category
- Medical Equipment Manufacturing
- Headquarters
- Burlington, MA
- Type
- Public Company
- Founded
- 2003
- Followers
- 29,370
- Specialties
- Deep TMS (Transcranial Magnetic Stimluation), Brain Disorder Treatment, Medical Devices, neuromodulation, mental health, Brain, Neurology, Depression, Obsessive-Compulsive Disorder, Anxious Depression, and Smoking Addiction
- Locations
- 1 Van de Graaf Drive Burlington, MA 01803, US
300 Knickerbocker Road Cresskill, NJ 07626, US
19 Hartom Jerusalem, IL
Funding
Total rounds: 5
Last round: Post IPO equity, Oct 30, 2024
Last round amount: US$ 20.0M
Jobs
Open roles: 13